Patients suffering from catheter-related bloodstream infections could be treated with Citius Pharmaceuticals antibiotic lock solution after it achieved 92 milestone events in its phase 3 trial.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
With the release of its new Sight OLO artificial intelligence based blood analyzer, Sight Diagnostics hopes to offer DCTs reliable, easy-to-use testing.
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
Key Biologics and Cascade Regional Blood Services’ multi-year agreement will provide researchers with the critical raw material needed for developing cell- and gene-based therapies.
Shire has begun adding capability within its own network to manufacture the Hereditary Angioedema (HAE) product Cinryze, currently being made by Dutch CMO Sanquin.
Acticor Biotech has made a deal with Merck KGaA’s CMO MilliporeSigma to use its Provantage End-to-End services to make its anti-thrombotic antibody fragment ACT-017 for stroke.
Researchers have developed a new magnetically controlled drug that can dissolve clots up to 4,000 times more efficiently than ordinary enzyme-based drugs.
Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.
A new 3D model of the human liver that even has its own blood
supply could pump new life into drug safety tests by predicting
problems earlier and cut down on animal experiments.
Taiwan looks to benefit from a new alliance with Canada-based
ProMetic BioTherapeutics, which will provide a proprietary
manufacturing process to extract plasma proteins for drugs.
Several groups of scientists are developing compounds that slowly
release carbon monoxide directly into the bloodstream and that
could be used to treat diseases as diverse as high blood pressure,
heart disease and cancer.
The US Food and Drug Administration (FDA) has decided against
restricting the use of drug-eluting cardiac stents after a two-day
investigation into their potential to increase blood clots.
GTC Biotherapeutics and LFB Biotechnologies have entered into a
collaboration, which focuses on recombinant plasma proteins and
monoclonal antibodies (mAbs) to eventually develop a robust
pipeline for treating conditions such as haemophilia.
Researchers have found that a simple and inexpensive test can help
determine which patients with venous thromboembolism (VTE) are at
low risk for recurrence and can therefore avoid unnecessary and
potentially dangerous long-term anticoagulant...
Northfield Laboratories, a company specialising in the development
of human hemoglobin-based oxygen carriers, has splashed out $6.7m
(€5.2m) to buy a plant it previously leased in Illinois, as it
edges closer to commercialising its...
BioMedica Diagnostic is to open a manufacturing facility in Ghana
that will produce affordable laboratory equipment whilst meeting
the need for a home grown African diagnostic solution for the
Continent's medical problems.
A new one-step test that is designed to distinguish
heterophile-positive, infectious mononucleosis (IM) from other
common symptomatic infections, claims to deliver a 99 per cent
sensitivity score, significantly improving on current...
Jacobs Engineering Group has been chosen to upgrade and expand
GlaxoSmithKline's (GSK) manufacturing capability at its Irish
plant, as well as develop a new biological manufacturing facility
for US firm Northfield Laboratories.
A member of a new class of drugs may increase survival in patients
with myelodysplastic syndrome (MDS), and could become the new
standard of therapy for this group of pre-cancer disorders, said
researchers.
Oxygen therapeutics company Biopure has announced another $3
million (€2.5 million) public offering to boost its working
capital, despite its major drug for humans, Hemopure, an artificial
blood product, being licensed only in South...
Scientists at the Georgia Institute of Technology have developed a
small handheld device that makes finding veins easier and quicker,
saving time and money.
Drugs, which stick to a key protein in the bloodstream, could help
to create drugs that are delivered more effectively to organs in
the body. The latest research, which points to a more effective
delivery of therapy, could improve...
NMT Medical announced that the company has received approvals to
initiate studies designed to evaluate its new closure technology.
The collagen matrix used in the technology has the potential to
deliver and localise drugs and other...
Croatia's Pliva, the largest pharmaceutical company in Eastern
Europe, has teamed up with Australia's Mayne Pharma to hasten the
development of two 'generic' biologic drugs.
Pall is gearing up to launch a new filter technology in Europe that
can remove prions - the infectious agents that cause mad cow
disease and its human form Creutzfeldt-Jakob disease (vCJD) - from
blood and blood products.
As the pharmaceutical industry gears up to use radiofrequency
identification for supply chain management, medical suppliers in
Germany have already adopted the technology to track blood products
and no plan to use it safeguard quality.
Dutch drug delivery company OctoPlus has licensed two
biodegradeable polymers to SurModics that can be used to coat
medical devices and deliver drugs into the surrounding tissues.
AstraZeneca has been granted approval for a new drug - the first in
its class - for the prevention of blood clotting complications
(venous thromboembolism) in major orthopaedic (hip or knee
replacement) surgery. It is the first new...
